Frank A Sinicrope1, Qian Shi2, Aurelie Catteau3, Graham M Poage3, Tyler J Zemla2, Bernhard Mlecnik4,5, Al B Benson6, Sharlene Gill7, Richard M Goldberg8, Morton S Kahlenberg9, Suresh G Nair10, Anthony F Shields11, Thomas C Smyrk1, Jerome Galon4, Steven R Alberts1. 1. Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN. 2. Alliance Statistics and Data Center, Rochester, MN. 3. Veracyte Inc, San Francisco, CA. 4. INSERM, UMRS 1138, Laboratory of Integrative Cancer Immunology, Universite Paris Descartes, Paris, France. 5. Inovarion, Paris, France. 6. Northwestern University, Chicago, IL. 7. British Columbia Cancer Agency-Vancouver Cancer Center, Vancouver, BC, Canada. 8. West Virginia Cancer Institute, Morgantown, WV. 9. Surgical Oncology Associates of South Texas, San Antonio, TX. 10. Lehigh Valley Hospital, Allentown, PA. 11. Karmanos Cancer Institute, Detroit, MI.
Abstract
PURPOSE: The recommended duration of adjuvant fluoropyrimidine and oxaliplatin chemotherapy for patients with stage III colon cancer is based on tumor classification into clinically low-risk (T1-3 N1) and high-risk (T4 or N2) groups. We determined whether Immunoscore can enhance prognostication within these risk groups. MATERIALS AND METHODS: Patients with stage III colon carcinomas (N = 600) were randomly selected from the infusional fluorouracil, leucovorin, and oxaliplatin arm of adjuvant trial NCCTG N0147 (Alliance for Clinical Trials in Oncology). Tumors were evaluated for Immunoscore that quantifies CD3+ and CD8+ T-cell densities in the tumor center and invasive margin by digital image analysis. Disease-free survival (DFS) by Immunoscore was analyzed using a multivariable Cox regression model in each risk group with adjustment for covariates including KRAS, BRAFV600E, and mismatch repair status. RESULTS: Of 559 cancers with Immunoscore data, 299 (53.5%) were classified as clinically low-risk (T1-3 N1) and 260 (46.5%) as clinically high-risk (T4 and/or N2). Among patients with low-risk tumors, those with Immunoscore-Low versus Immunoscore-High tumors had significantly worse 5-year DFS rates (77.5% v 91.8%; hazard ratio, 1.70; 95% CI, 1.03 to 2.79; P = .037). Among patients with high-risk tumors, those with Immunoscore-Low versus Immunoscore-High tumors also had significantly worse DFS (55.3% v 70.3%; hazard ratio, 1.65; 95% CI, 1.11 to 2.47; P = .013). Tumors that were low-risk/Immunoscore-Low had similar outcomes as did tumors that were high-risk/Immunoscore-High (P = .174). Prognostication was significantly improved in multivariable models where Immunoscore was added to clinical risk parameters and limited biomarkers (likelihood ratio test P = .0003). CONCLUSION: Immunoscore can refine patient prognosis beyond clinical risk group classification, suggesting its potential utility for adjuvant decision making.
PURPOSE: The recommended duration of adjuvant fluoropyrimidine and oxaliplatin chemotherapy for patients with stage III colon cancer is based on tumor classification into clinically low-risk (T1-3 N1) and high-risk (T4 or N2) groups. We determined whether Immunoscore can enhance prognostication within these risk groups. MATERIALS AND METHODS: Patients with stage III colon carcinomas (N = 600) were randomly selected from the infusional fluorouracil, leucovorin, and oxaliplatin arm of adjuvant trial NCCTG N0147 (Alliance for Clinical Trials in Oncology). Tumors were evaluated for Immunoscore that quantifies CD3+ and CD8+ T-cell densities in the tumor center and invasive margin by digital image analysis. Disease-free survival (DFS) by Immunoscore was analyzed using a multivariable Cox regression model in each risk group with adjustment for covariates including KRAS, BRAFV600E, and mismatch repair status. RESULTS: Of 559 cancers with Immunoscore data, 299 (53.5%) were classified as clinically low-risk (T1-3 N1) and 260 (46.5%) as clinically high-risk (T4 and/or N2). Among patients with low-risk tumors, those with Immunoscore-Low versus Immunoscore-High tumors had significantly worse 5-year DFS rates (77.5% v 91.8%; hazard ratio, 1.70; 95% CI, 1.03 to 2.79; P = .037). Among patients with high-risk tumors, those with Immunoscore-Low versus Immunoscore-High tumors also had significantly worse DFS (55.3% v 70.3%; hazard ratio, 1.65; 95% CI, 1.11 to 2.47; P = .013). Tumors that were low-risk/Immunoscore-Low had similar outcomes as did tumors that were high-risk/Immunoscore-High (P = .174). Prognostication was significantly improved in multivariable models where Immunoscore was added to clinical risk parameters and limited biomarkers (likelihood ratio test P = .0003). CONCLUSION: Immunoscore can refine patient prognosis beyond clinical risk group classification, suggesting its potential utility for adjuvant decision making.
Authors: Steven R Alberts; Daniel J Sargent; Suresh Nair; Michelle R Mahoney; Margaret Mooney; Stephen N Thibodeau; Thomas C Smyrk; Frank A Sinicrope; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Anthony F Shields; James T Quesenberry; Thomas A Webb; Gist H Farr; Barbara A Pockaj; Axel Grothey; Richard M Goldberg Journal: JAMA Date: 2012-04-04 Impact factor: 56.272
Authors: G Argilés; J Tabernero; R Labianca; D Hochhauser; R Salazar; T Iveson; P Laurent-Puig; P Quirke; T Yoshino; J Taieb; E Martinelli; D Arnold Journal: Ann Oncol Date: 2020-07-20 Impact factor: 32.976
Authors: Bernhard Mlecnik; Gabriela Bindea; Helen K Angell; Pauline Maby; Mihaela Angelova; David Tougeron; Sarah E Church; Lucie Lafontaine; Maria Fischer; Tessa Fredriksen; Maristella Sasso; Amélie M Bilocq; Amos Kirilovsky; Anna C Obenauf; Mohamad Hamieh; Anne Berger; Patrick Bruneval; Jean-Jacques Tuech; Jean-Christophe Sabourin; Florence Le Pessot; Jacques Mauillon; Arash Rafii; Pierre Laurent-Puig; Michael R Speicher; Zlatko Trajanoski; Pierre Michel; Richard Sesboüe; Thierry Frebourg; Franck Pagès; Viia Valge-Archer; Jean-Baptiste Latouche; Jérôme Galon Journal: Immunity Date: 2016-03-15 Impact factor: 31.745
Authors: Axel Grothey; Alberto F Sobrero; Anthony F Shields; Takayuki Yoshino; James Paul; Julien Taieb; John Souglakos; Qian Shi; Rachel Kerr; Roberto Labianca; Jeffrey A Meyerhardt; Dewi Vernerey; Takeharu Yamanaka; Ioannis Boukovinas; Jeffrey P Meyers; Lindsay A Renfro; Donna Niedzwiecki; Toshiaki Watanabe; Valter Torri; Mark Saunders; Daniel J Sargent; Thierry Andre; Timothy Iveson Journal: N Engl J Med Date: 2018-03-29 Impact factor: 91.245
Authors: F Pagès; T André; J Taieb; D Vernerey; J Henriques; C Borg; F Marliot; R Ben Jannet; C Louvet; L Mineur; J Bennouna; J Desrame; R Faroux; A Kirilovsky; A Duval; P Laurent-Puig; M Svrcek; F Hermitte; A Catteau; J Galon; J-F Emile Journal: Ann Oncol Date: 2020-04-12 Impact factor: 32.976
Authors: Bernhard Mlecnik; Carlo Bifulco; Gabriela Bindea; Florence Marliot; Alessandro Lugli; J Jack Lee; Inti Zlobec; Tilman T Rau; Martin D Berger; Iris D Nagtegaal; Elisa Vink-Börger; Arndt Hartmann; Carol Geppert; Julie Kolwelter; Susanne Merkel; Robert Grützmann; Marc Van den Eynde; Anne Jouret-Mourin; Alex Kartheuser; Daniel Léonard; Christophe Remue; Julia Y Wang; Prashant Bavi; Michael H A Roehrl; Pamela S Ohashi; Linh T Nguyen; SeongJun Han; Heather L MacGregor; Sara Hafezi-Bakhtiari; Bradly G Wouters; Giuseppe V Masucci; Emilia K Andersson; Eva Zavadova; Michal Vocka; Jan Spacek; Lubos Petruzelka; Bohuslav Konopasek; Pavel Dundr; Helena Skalova; Kristyna Nemejcova; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Gennaro Ciliberto; Michele Maio; Luigi Laghi; Fabio Grizzi; Tessa Fredriksen; Bénédicte Buttard; Lucie Lafontaine; Daniela Bruni; Anastasia Lanzi; Carine El Sissy; Nacilla Haicheur; Amos Kirilovsky; Anne Berger; Christine Lagorce; Christopher Paustian; Carmen Ballesteros-Merino; Jeroen Dijkstra; Carlijn van de Water; Shannon van Lent-van Vliet; Nikki Knijn; Ana-Maria Muşină; Dragos-Viorel Scripcariu; Boryana Popivanova; Mingli Xu; Tomonobu Fujita; Shoichi Hazama; Nobuaki Suzuki; Hiroaki Nagano; Kiyotaka Okuno; Toshihiko Torigoe; Noriyuki Sato; Tomohisa Furuhata; Ichiro Takemasa; Kyogo Itoh; Prabhu S Patel; Hemangini H Vora; Birva Shah; Jayendrakumar B Patel; Kruti N Rajvik; Shashank J Pandya; Shilin N Shukla; Yili Wang; Guanjun Zhang; Yutaka Kawakami; Francesco M Marincola; Paolo A Ascierto; Bernard A Fox; Franck Pagès; Jérôme Galon Journal: J Clin Oncol Date: 2020-09-08 Impact factor: 44.544
Authors: Romain Cohen; Julien Taieb; Jack Fiskum; Greg Yothers; Richard Goldberg; Takayuki Yoshino; Steven Alberts; Carmen Allegra; Aimery de Gramont; Jean-Francois Seitz; Michael O'Connell; Daniel Haller; Norman Wolmark; Charles Erlichman; Alberto Zaniboni; Sara Lonardi; Rachel Kerr; Axel Grothey; Frank A Sinicrope; Thierry André; Qian Shi Journal: J Clin Oncol Date: 2020-12-23 Impact factor: 44.544
Authors: Frank A Sinicrope; Qian Shi; Fabienne Hermitte; Tyler J Zemla; Bernhard Mlecnik; Al B Benson; Sharlene Gill; Richard M Goldberg; Morton S Kahlenberg; Suresh G Nair; Anthony F Shields; Thomas C Smyrk; Jerome Galon; Steven R Alberts Journal: JNCI Cancer Spectr Date: 2020-04-05